At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
XM02 Filgrastim +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating XM02 Filgrastim, Filgrastim, and 3 other interventions for Multiple Myeloma and Lymphoma, Non-Hodgkin. Completed, enrolled 100 participants across 1 site.
Detailed Summary
This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Lymphoma, Non-Hodgkin
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartAug 2014
Primary CompletionJun 2016
Study CompletionSep 2016
TodayJul 2026
First PostedMar 27, 2014
Enrollment StartAug 20, 2014
Primary CompletionJun 10, 2016
Study CompletionSep 18, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.3 years ago
Interventions
XM02 Filgrastimdrug
Filgrastimdrug
Apheresisprocedure
Plerixafordrug
Stem Cell Transplantprocedure